Announcements
- aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- aTyr Pharma to Present Poster Describing Efzofitimod’s Mechanism of Action at the American Thoracic Society 2024 International Conference
- aTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
- aTyr Pharma to Present at Upcoming Investor Conferences
- aTyr Pharma Announces First Quarter 2024 Results and Provides Corporate Update
- aTyr Pharma to Participate in April Investor Conferences
- aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update
- aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results
- aTyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial Participants
- aTyr Pharma to Present Posters Highlighting Importance of Neuropilin-2 in Immune Regulation at Keystone Symposia on Myeloid Cell Diversity
More ▼
Key statistics
As of last trade, aTyr Pharma Inc (471A:DEU) traded at 1.60, 62.44% above the 52 week low of 0.985 set on Nov 15, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.61 |
---|---|
High | 1.67 |
Low | 1.58 |
Bid | 1.60 |
Offer | 1.67 |
Previous close | 1.61 |
Average volume | 2.47k |
---|---|
Shares outstanding | 69.01m |
Free float | 67.23m |
P/E (TTM) | -- |
Market cap | 123.53m USD |
EPS (TTM) | -0.9029 USD |
Data delayed at least 15 minutes, as of May 28 2024.
More ▼